OBJECTIVE: It has been reported that aberrant DNA methylation can be associated with HPV infection and cervical tumorigenesis. The aim of this study was to evaluate the possibility that polymorphic variants of genes that may affect DNA methylation status are associated with the risk of cervical cancer in the Polish population. DESIGN AND METHOD: Employing PCR-RFLPs and HRM analyses, we examined the prevalence of BHMT Arg239Gln (rs3733890), MTR Asp919Gly (rs1805087), MTHFR Ala222Val (rs1801133), MTHFD1 Arg653Gln (rs2236225) and MTRR Ile22Met (rs1801394) genotypes and alleles in patients with advanced cervical cancer (n=124) and controls (n=168). RESULTS: The odds ratio (OR) for BHMT Gln/Gln genotype was 0.433 (95% CI=0.1780-1.054; p=0.0602). The OR for patients having the BHMT Arg/Gln or Gln/Gln genotypes was 0.579 (95% CI=0.3622-0.924; p=0.0216). We also observed a significantly higher frequency of the BHMT 239Gln allele in controls than in patients, p=0.0165. The genotype and allele frequencies of the MTR Asp919Gly, MTHFR Ala222Val, MTHFD1 Arg653Gln and MTRR Ile22Met gene variants did not display statistical differences between patients with cervical cancer and controls. We also did not find a significant association between the distribution of any genotypes or alleles and cancer characteristics. CONCLUSION: Our results might suggest the protective role of the BHMT 239Gln variant in cervical cancer incidence.
OBJECTIVE: It has been reported that aberrant DNA methylation can be associated with HPV infection and cervical tumorigenesis. The aim of this study was to evaluate the possibility that polymorphic variants of genes that may affect DNA methylation status are associated with the risk of cervical cancer in the Polish population. DESIGN AND METHOD: Employing PCR-RFLPs and HRM analyses, we examined the prevalence of BHMT Arg239Gln (rs3733890), MTR Asp919Gly (rs1805087), MTHFR Ala222Val (rs1801133), MTHFD1 Arg653Gln (rs2236225) and MTRRIle22Met (rs1801394) genotypes and alleles in patients with advanced cervical cancer (n=124) and controls (n=168). RESULTS: The odds ratio (OR) for BHMTGln/Gln genotype was 0.433 (95% CI=0.1780-1.054; p=0.0602). The OR for patients having the BHMTArg/Gln or Gln/Gln genotypes was 0.579 (95% CI=0.3622-0.924; p=0.0216). We also observed a significantly higher frequency of the BHMT 239Gln allele in controls than in patients, p=0.0165. The genotype and allele frequencies of the MTR Asp919Gly, MTHFR Ala222Val, MTHFD1 Arg653Gln and MTRRIle22Met gene variants did not display statistical differences between patients with cervical cancer and controls. We also did not find a significant association between the distribution of any genotypes or alleles and cancer characteristics. CONCLUSION: Our results might suggest the protective role of the BHMT 239Gln variant in cervical cancer incidence.
Authors: Piotr Pawlik; Adrianna Mostowska; Margarita Lianeri; Stefan Sajdak; Helena Kędzia; Paweł P Jagodzinski Journal: Mol Biol Rep Date: 2011-12-20 Impact factor: 2.316
Authors: Márcia R Amorim; Cláudia M Moura; Aline D Gomes; Hazel N Barboza; Roberta B Lopes; Márcia G Ribeiro; Marcelo A Costa Lima Journal: Mol Biol Rep Date: 2013-05-05 Impact factor: 2.316
Authors: Ya Li Luo; Ping Ye; Qiong Hua Zhang; Ting Ting Hu; Min Hong Luo; Mei Qing Li; Qing Chen Journal: PLoS One Date: 2012-09-28 Impact factor: 3.240